Company news
Resverlogix Corp. (TSX:RVX) news
Resverlogix Corp. news releases on 6ix. Latest, Jun 22, 2015: Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority
Press releases — page 3
Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority
June 22, 2015
Resverlogix to Present at the 2015 Bio International Convention
June 17, 2015
Resverlogix Reports on the Beneficial Effects of RVX-208 on Glucose Metabolism in Prediabetes Mellitus at the American Diabetes Association's (ADA) Scientific Sessions in Boston, MA
June 8, 2015
Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)
June 1, 2015
Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement
April 27, 2015
Resverlogix Receives Two Patents for RVX-208 in China
April 7, 2015
Resverlogix Presents at the Prestigious American College of Cardiology 64th Annual Scientific Session & Expo (ACC.15)
March 16, 2015
Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program
March 4, 2015
Resverlogix Presents at BIO CEO & Investor Conference
February 10, 2015
Resverlogix Presents at Biotech Showcase During JP Morgan Week
January 13, 2015
Resverlogix Names Michael Sweeney, M.D., as Senior Vice President of Clinical Development
November 3, 2014
Resverlogix Announces Annual General Meeting Voting Results
October 8, 2014
Resverlogix Corporate Update Conference Call & Webcast Announcement
October 1, 2014
RVX-208 Leads to a 77% Relative Risk Reduction of Major Adverse Cardiovascular Events (MACE) in Patients with Diabetes Mellitus
September 2, 2014
Resverlogix Corp. Closes Additional $30 million from Citibank Loan
August 15, 2014
Resverlogix Corp. Shareholders Approve Additional $30 million from Citibank Loan
August 13, 2014
RVX-208 Reduces Major Adverse Cardiovascular Events (MACE) Significantly in Patients with Diabetes Mellitus
July 23, 2014
Resverlogix Secures an Additional $30 million from Citibank Loan
July 3, 2014
Resverlogix Closes $2.3 million Private Placement
June 11, 2014
Leading Life Science Publication SciBX Highlights RVX-208
May 21, 2014
Cleveland Clinic Presents RVX-208 Data at American College of Cardiology (ACC) Conference in Washington DC March 31, 2014
March 31, 2014
Resverlogix Update
March 17, 2014
Resverlogix Board Update
February 11, 2014
Resverlogix Conference Call & Webcast Announcement
February 6, 2014
Resverlogix Announces Combined RVX-208 findings from SUSTAIN & ASSURE Phase 2b Trials
January 15, 2014
Publications Confirm RVX-208 is a Unique Selective BET Bromodomain Antagonist
January 2, 2014
Resverlogix Completes Enrollment of Phase 2 Clinical Trial of RVX-208 in Patients with Pre-Diabetes Mellitus
December 23, 2013
Resverlogix Announces Two New Findings from the ASSURE Trial Relating to Inflammation and Plaque Vulnerability
November 4, 2013
Further Analysis of the ASSURE Data Finds a Responder Group for RVX-208 with Statistically Significant Regression of Coronary Atherosclerosis
September 3, 2013
Resverlogix Announces a Corporate Update Conference Call & Webcast
August 29, 2013
Resverlogix Closes $1.6 million Private Placement
August 14, 2013
Resverlogix Announces $1.6 million Private Placement
August 12, 2013
Resverlogix Corporation is Featured as the Daily Momentum Gainer to Watch on Smallcappower.com
July 5, 2013
Resverlogix to host Conference Call & Webcast with Q&A
June 28, 2013
Resverlogix Reports Top-Line Results from ASSURE Clinical Trial
June 27, 2013
Zenith Epigenetics Corp. commences operations
June 3, 2013
Resverlogix Corp. announces completion of spin-out transaction
June 3, 2013
Resverlogix Corp. shareholders approve plan of arrangement
May 28, 2013
Resverlogix Announces Details of Anticipated Distribution of Newco Shares
May 27, 2013
Resverlogix's Board Approves Arrangement to Spin-Out RVX Therapeutics Inc. and Confirms Special Meeting of Shareholders
May 1, 2013
Resverlogix Completes Dosing In ASSURE Clinical Trial
April 18, 2013
Resverlogix to Spin-out RVX Therapeutics Inc. to Shareholders
April 8, 2013
Resverlogix Secures Increase to Citibank Loan to $38.8 million
March 11, 2013
Resverlogix comments on steady climb of share price
January 31, 2013
Resverlogix Initiates Phase 2 Clinical Trial of RVX-208 in Patients with Pre-Diabetes Mellitus
October 16, 2012
Resverlogix Completes Enrollment In ASSURE Trial
September 26, 2012
Resverlogix's BET Protein Inhibitor RVX-208 Meets Primary Endpoint in SUSTAIN Clinical Trial in Patients With High Risk Cardiovascular Disease
August 28, 2012
Resverlogix Secures $25 Million, Five-Year Term Loan
August 26, 2012
Resverlogix Establishes Clinical & Scientific Advisory Board to Support the Clinical Development of RVX-208 and Other Bromodomain Inhibitors in Neurodegenerative Diseases
July 16, 2012
Resverlogix Completes Dosing of RVX-208 in SUSTAIN, a Phase 2b Clinical Trial Targeting High-Risk Cardiovascular Disease Patients
May 9, 2012